Research programme: mitochondrial protein modulators - Cardero Therapeutics/Sphaera Pharma

Drug Profile

Research programme: mitochondrial protein modulators - Cardero Therapeutics/Sphaera Pharma

Latest Information Update: 11 Feb 2016

Price : $50

At a glance

  • Originator Cardero Therapeutics
  • Developer Cardero Therapeutics; Sphaera Pharma
  • Class
  • Mechanism of Action Mitochondrial protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Cerebrovascular disorders; Metabolic disorders

Most Recent Events

  • 11 Feb 2016 Early research development is ongoing in USA (Sphaera Pharma website, February 2016)
  • 31 Dec 2010 Early research in Metabolic disorders in USA (unspecified route)
  • 31 Dec 2010 Early research in Cerebrovascular disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top